TY - JOUR
T1 - Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test
AU - Hoste, Alexis C. R.
AU - Venteo, Angel
AU - Fresco-Taboada, Alba
AU - Tapia, Istar
AU - Monedero, Alejandro
AU - López, Lissette
AU - Jebbink, Maarten F.
AU - Pérez-Ramírez, Elisa
AU - Jimenez-Clavero, Miguel Angel
AU - Almonacid, Mercedes
AU - Muñoz, Patricia
AU - Guinea, Jesus
AU - Vela, Carmen
AU - van der Hoek, Lia
AU - Rueda, Paloma
AU - Sastre, Patricia
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)] to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2% and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered patients and identification of asymptomatic individuals.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)] to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2% and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered patients and identification of asymptomatic individuals.
KW - COVID-19
KW - Diagnosis
KW - ELISA
KW - LFA
KW - SARS-CoV-2
KW - Serology
UR - http://www.scopus.com/inward/record.url?scp=85090043845&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.diagmicrobio.2020.115167
DO - https://doi.org/10.1016/j.diagmicrobio.2020.115167
M3 - Article
C2 - 32890908
SN - 0732-8893
VL - 98
JO - Diagnostic microbiology and infectious disease
JF - Diagnostic microbiology and infectious disease
IS - 4
M1 - 115167
ER -